Austin, Texas – Solomon Mushtivich, head of clinical diagnostic in Natera, Inc. (NASDAQ :), recently sold a large part of his property in the company. The sale comes at a time when Natera arrow showed a great power, with a return of 159 % over the past year, and the company got the market value of $ 22.12 billion. According to submitting a file with the Securities and Exchange Committee, Moshkevich sold a total of 24,861 shares of joint shares in Natera on January 22, 2025, when he achieved about $ 4.1 million. These transactions occurred at prices ranging from $ 164.95 to $ 171.95 per share.
After these sales, Moshkevich maintains 140,684 shares in the company. According to the deposit, sales were made to meet the tax blocking obligations related to installing restricted stock units, according to the pre -trading plan. InvestingPro The analysis shows that Natera maintains a strong financial position with a “good” healthy result and strong liquidity, as shown in the current percentage 4.39. For deeper visions about interior trading and comprehensive financial analysis, investors can access the detailed professional research report, exclusively available on InvestingPro.
In other recent news, Nata Inc . The waves were made in the industry. Barclays (LON 🙂 recently promoted the company's shares rating to weight gain with the goal of $ 200, indicating its expansion in new markets and impressive growth of 55 % over the past twelve months. Luke Sergut analyst Natra's Evolution from NIPT NGS is highlighted to become a leading player in the NIPT market, extending it to NGS oncology and members health test.
NATERA has also expanded the patent violations against nickeh (NASDAQ 🙂 includes the radar test. Although a setback in a wrong advertising lawsuit against Guarding health (Nasdaq :), Natera plans to request the court to cancel the ruling. In addition, an agreement was modified with Dr. Rabinowitz, CEO, to continue his role under certain circumstances.
TD COWEN repeated a purchase on Natera shares, raising the target price from $ 175 to $ 195, reflecting confidence in the future performance of the company. Likewise, Baird and Jefferies also maintained favorable classifications on Natera shares and raised their prices.
Finally, Natera reported record revenues of $ 439.8 million, which represents an increase of 64 % over the previous year, and conducted 137,000 tumors. These recent developments provide investors with an insight into the current situation of Natera and future prospects.
This article was created with the support of artificial intelligence and reviewed by an editor. For more information, see T&C.
